Motley Fool

24 Jul Stock Analysis

Subscriber growth may be abnormally slow, but the business model itself is plenty viable.

24 Jul Stock Analysis

The big bank reported a rare revenue miss, but that doesn’t tell the full story.

24 Jul Stock Analysis

The short answer: They were impressive.

24 Jul Stock Analysis

This unlikely meme stock gives bulls and bears a lot to chew on.

24 Jul Business

Let’s clear the air about Intel’s struggles and ambitions.

24 Jul Stock Analysis

This app for healthcare professionals could be an interesting investment.

24 Jul Stock Analysis

Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be…

24 Jul Stock Analysis

These companies pay hefty dividends and have big capital appreciation potential.

24 Jul Stock Analysis

Which of these two high-growth chipmakers deserves your money?

24 Jul Stock Analysis

Jazz Pharma is not the most popular drugmaker, but it is definitely worth a second look.